Literature DB >> 21964595

Negative cross talk between NFAT1 and Stat5 signaling in breast cancer.

Jiamao Zheng1, Feng Fang, Xianke Zeng, Terry R Medler, Alyson A Fiorillo, Charles V Clevenger.   

Abstract

The molecular mechanisms that modulate the activity of the signal transducers and activators of transcription 5 (Stat5) during the progression of breast cancer remain elusive. Here, we present evidence that the calcineurin/nuclear factor of activated T cells (NFAT) pathway negatively regulates the activation of Stat5, and vice versa in breast cancer. NFAT1 interacts with Stat5 in breast cancer cells, and their physical association is mediated by the DNA binding and transactivation domains of Stat5. Ectopically expressed NFAT1 is capable of inhibiting Stat5-dependent functions, including Stat5 transactivation, Stat5-mediated transcription of the downstream target gene expression, and binding of Stat5a to the Stat5 target promoter. By contrast, overexpression of a selective NFAT inhibitor VIVIT reversed NFAT1-mediated suppression of Stat5-dependent gene expression, whereas silencing of NFAT1 through RNA interference enhanced prolactin-induced, Stat5-mediated gene transcription, and breast cancer cell proliferation. A reciprocal inhibitory effect of Stat5 activity on NFAT1 signaling was also observed, implying these two signaling cascades antagonize each other in breast cancer. Importantly, analysis of a matched breast cancer progression tissue microarray revealed a negative correlation between levels of NFAT1 and Stat5 (pY694) during the progression of breast cancer. Taken together, these studies highlight a novel negative cross talk between the NFAT1- and Stat5-signaling cascades that may affect breast tumor formation, growth, and metastasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21964595      PMCID: PMC3231824          DOI: 10.1210/me.2011-1141

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  37 in total

1.  Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A.

Authors:  J Aramburu; M B Yaffe; C López-Rodríguez; L C Cantley; P G Hogan; A Rao
Journal:  Science       Date:  1999-09-24       Impact factor: 47.728

2.  Stat5a/b are essential for normal lymphoid development and differentiation.

Authors:  Zhengju Yao; Yongzhi Cui; Wendy T Watford; Jay H Bream; Kunihiro Yamaoka; Bruce D Hissong; Denise Li; Scott K Durum; Qiong Jiang; Avinash Bhandoola; Lothar Hennighausen; John J O'Shea
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-17       Impact factor: 11.205

Review 3.  STATs and gene regulation.

Authors:  J E Darnell
Journal:  Science       Date:  1997-09-12       Impact factor: 47.728

4.  Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells.

Authors:  Ahmed S Sultan; Jianwu Xie; Matthew J LeBaron; Erica L Ealley; Marja T Nevalainen; Hallgeir Rui
Journal:  Oncogene       Date:  2005-01-27       Impact factor: 9.867

5.  Prolactin signals via Stat5 and Oct-1 to the proximal cyclin D1 promoter.

Authors:  Jennifer L Brockman; Linda A Schuler
Journal:  Mol Cell Endocrinol       Date:  2005-07-15       Impact factor: 4.102

6.  Two contact regions between Stat1 and CBP/p300 in interferon gamma signaling.

Authors:  J J Zhang; U Vinkemeier; W Gu; D Chakravarti; C M Horvath; J E Darnell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

7.  Integrin alpha6beta4 promotes expression of autotaxin/ENPP2 autocrine motility factor in breast carcinoma cells.

Authors:  Min Chen; Kathleen L O'Connor
Journal:  Oncogene       Date:  2005-07-28       Impact factor: 9.867

8.  Functional association of Nmi with Stat5 and Stat1 in IL-2- and IFNgamma-mediated signaling.

Authors:  M Zhu; S John; M Berg; W J Leonard
Journal:  Cell       Date:  1999-01-08       Impact factor: 41.582

9.  Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation.

Authors:  M Onishi; T Nosaka; K Misawa; A L Mui; D Gorman; M McMahon; A Miyajima; T Kitamura
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

10.  Quantification of PRL/Stat5 signaling with a novel pGL4-CISH reporter.

Authors:  Feng Fang; Giovanni Antico; Jiamao Zheng; Charles V Clevenger
Journal:  BMC Biotechnol       Date:  2008-02-06       Impact factor: 2.563

View more
  13 in total

1.  Xtalk: a path-based approach for identifying crosstalk between signaling pathways.

Authors:  Allison N Tegge; Nicholas Sharp; T M Murali
Journal:  Bioinformatics       Date:  2015-09-23       Impact factor: 6.937

2.  Rapamycin reduces fibroblast proliferation without causing quiescence and induces STAT5A/B-mediated cytokine production.

Authors:  Zoe E Gillespie; Kimberly MacKay; Michelle Sander; Brett Trost; Wojciech Dawicki; Aruna Wickramarathna; John Gordon; Mark Eramian; Ian R Kill; Joanna M Bridger; Anthony Kusalik; Jennifer A Mitchell; Christopher H Eskiw
Journal:  Nucleus       Date:  2015       Impact factor: 4.197

Review 3.  NFAT as cancer target: mission possible?

Authors:  Jiang-Jiang Qin; Subhasree Nag; Wei Wang; Jianwei Zhou; Wei-Dong Zhang; Hui Wang; Ruiwen Zhang
Journal:  Biochim Biophys Acta       Date:  2014-07-26

4.  SOCE-mediated NFAT1-NOX2-NLRP1 inflammasome involves in lipopolysaccharide-induced neuronal damage and Aβ generation.

Authors:  Zhenghao Sun; Xuewang Li; Liu Yang; Xianan Dong; Yuli Han; Yan Li; Jing Luo; Weizu Li
Journal:  Mol Neurobiol       Date:  2022-03-14       Impact factor: 5.590

Review 5.  NFAT gene family in inflammation and cancer.

Authors:  M-G Pan; Y Xiong; F Chen
Journal:  Curr Mol Med       Date:  2013-05       Impact factor: 2.222

6.  Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA.

Authors:  Jiang-Jiang Qin; Wei Wang; Sukesh Voruganti; Hui Wang; Wei-Dong Zhang; Ruiwen Zhang
Journal:  Oncotarget       Date:  2015-10-20

7.  NFAT1 is highly expressed in, and regulates the invasion of, glioblastoma multiforme cells.

Authors:  Xinxin Tie; Sheng Han; Lingxuan Meng; Yunjie Wang; Anhua Wu
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

8.  The 'N-factors' in pancreatic cancer: functional relevance of NF-κB, NFAT and Nrf2 in pancreatic cancer.

Authors:  A Arlt; H Schäfer; H Kalthoff
Journal:  Oncogenesis       Date:  2012-11-26       Impact factor: 7.485

9.  Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes.

Authors:  Amy R Peck; Agnieszka K Witkiewicz; Chengbao Liu; Alexander C Klimowicz; Ginger A Stringer; Edward Pequignot; Boris Freydin; Ning Yang; Adam Ertel; Thai H Tran; Melanie A Girondo; Anne L Rosenberg; Jeffrey A Hooke; Albert J Kovatich; Craig D Shriver; David L Rimm; Anthony M Magliocco; Terry Hyslop; Hallgeir Rui
Journal:  Breast Cancer Res       Date:  2012-10-04       Impact factor: 6.466

10.  Integrative genomic and transcriptomic analysis identified candidate genes implicated in the pathogenesis of hepatosplenic T-cell lymphoma.

Authors:  Julio Finalet Ferreiro; Leila Rouhigharabaei; Helena Urbankova; Jo-Anne van der Krogt; Lucienne Michaux; Shashirekha Shetty; Laszlo Krenacs; Thomas Tousseyn; Pascale De Paepe; Anne Uyttebroeck; Gregor Verhoef; Tom Taghon; Peter Vandenberghe; Jan Cools; Iwona Wlodarska
Journal:  PLoS One       Date:  2014-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.